MAPT and Alzheimer disease: Core diagnostic AD CSF biomarker (Aβ42, tau and p-tau) levels were distributed as expected across the three diagnosis groups: significantly lower levels of Aβ42 in AD patients and significantly higher levels of tau and p-tau in AD patients compared with SMC controls (Fig. 1c–e).